Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)

BACKGROUND: In the global phase III IMpassion031 study, neoadjuvant atezolizumab plus nab-paclitaxel/anthracycline-based chemotherapy improved pathological complete response in patients with early stage triple-negative breast cancer. Here, we report primary analysis results from a subgroup of Japane...

Descripción completa

Detalles Bibliográficos
Autores principales: Saji, Shigehira, Ohsumi, Shozo, Ito, Mitsuya, Hayashi, Naoki, Kobayashi, Kokoro, Masuda, Norikazu, Niikura, Naoki, Yamashita, Toshinari, Kiyama, Keiichiro, Hasegawa, Ayumi, Nakagawa, Shizuka, Hattori, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538755/
https://www.ncbi.nlm.nih.gov/pubmed/35750038
http://dx.doi.org/10.1093/jjco/hyac098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538755/
https://www.ncbi.nlm.nih.gov/pubmed/35750038
http://dx.doi.org/10.1093/jjco/hyac098

Ejemplares similares